Osler Diagnostics Valuation, Funding & Investors
Osler Diagnostics is valued at $89M as of December 2018.
Last Osler Diagnostics valuation
$89M
Series A · Dec 2018
Last Osler Diagnostics funding round
$85M
Series C · Nov 2022
Cumulative funding Osler Diagnostics raised
$178M
across 5 funding rounds
Key investors in Osler Diagnostics
Oxford Science Enterprises
M&G Investments
Lansdowne Partners
Braavos Investment Advisers
About Osler Diagnostics
Osler Diagnostics is an Oxford-headquartered medtech company spun out from the University of Oxford in 2017. It develops the Origin device, a portable analyzer for 25 blood biomarkers including cholesterol and HbA1c, targeting point-of-care testing in clinics and homes across Europe and Africa. Osler raised GBP 12 million in Series A funding in 2022.
Founded
2017
HQ
OxfordWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$89M (Dec 2018)
Osler Diagnostics Valuation
Osler Diagnostics is currently valued at $89M, based on its Series A in December 2018. Read the announcement ↗
Osler Diagnostics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Dec 2018 | Series A | $89M |
Osler Diagnostics Funding History
Osler Diagnostics has raised a total of $178M across 5 funding rounds.
Osler Diagnostics' first fundraising round was a $3M seed round in July 2016. The most recent completed round was a $85M Series C in November 2022.
Osler Diagnostics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Nov 2022 | Series C | Oxford Science Enterprises; Lansdowne Partners; M&G Investments; Braavos Investment Advisers | $85M | - | Osler Diagnostics, a UK-based medical diagnostic company founded in 2017 as a spinout from the University of Oxford, raised $85 million in a Series C financing round announced on November 7, 2022. The round included investment from strategic investor M&G Investments and existing investors Oxford Science Enterprises, Braavos Investment Advisers, and Lansdowne Partners. The company was developing the Osler Origin, a portable diagnostic device capable of performing a wide range of lab-quality tests rapidly, at low cost, and in an easy-to-use manner, designed to serve all major healthcare settings globally. The funding was intended to support advancement of the Osler Origin product through regulatory activities and toward market launch. The company was headquartered in Oxford, UK, and employed more than 100 staff members as of the financing announcement. |
| Nov 2020 | Series B | - | $47M | - | Osler Diagnostics, a University of Oxford spinout founded in 2017, develops the Osler Origin, a portable diagnostic device offering lab-quality testing for a wide range of tests in a rapid, low-cost, and easy-to-use format, targeting all major healthcare settings globally. The technology builds on decades of research from the department that invented the portable electrochemical blood glucose sensor, featuring proprietary Osler HemaTap sample addition, microfluidic preparation, and electrochemical biosensing. The company, headquartered in Oxford, UK, had over 100 employees by 2022. Around November 17, 2020, Osler Diagnostics raised £35M in a funding round, matching the approximate date of 20/11/2020 queried. Later, on November 7, 2022, Osler raised $85 million in Series C financing from strategic investor M&G Investments and existing backers including Oxford Science Enterprises, Braavos Investment Advisers, and Lansdowne Partners. The funds supported advancing the Osler Origin through regulatory activities toward market launch. Some reports noted this as £74m equivalent. The company continued operations, appointing a new CEO in a later development, with Connor Campbell transitioning from CEO by end-2025. Osler positions itself to transform healthcare by enabling accessible diagnostics anywhere, competing with limited existing portable solutions. |
| Dec 2018 | Series A | - | $39M | $89M | Osler Diagnostics, a medical diagnostic company spun out of the University of Oxford in 2017, develops the Osler Origin, a portable diagnostic platform capable of performing a wide range of high-performance tests rapidly and cost-effectively for use in various healthcare settings globally. The company aims to provide lab-quality diagnostics to anyone, anywhere, at any time, building on technology from the department that invented the portable blood glucose sensor. Subsequent developments include a Series C round of $85 million in November 2022 led by investors such as M&G Investments, Oxford Science Enterprises, Braavos Investment Advisers, and Lansdowne Partners to advance regulatory approval and market launch of Osler Origin. |
| Aug 2017 | Seed | - | $5M | - | Osler Diagnostics, formed out of the University of Oxford in 2017, develops portable diagnostic devices including the Osler Origin platform for lab-quality testing anywhere. The company originated from research on portable electrochemical blood glucose sensors. |
| Jul 2016 | Seed | - | $3M | - | Osler Diagnostics, originally founded in 2016 as Oxford Impedance Diagnostics, develops a handheld diagnostic device for detecting cancers, cardiovascular, and neurological diseases through biomarker analysis from a drop of blood using impedance and capacitance signals. The device enables lab-free testing, targeting accessibility in developing regions for epidemic mitigation like Ebola or Zika. In 2016, Osler raised $2.6M from investors including Oxford Sciences Innovation, Bio-Rad Laboratories, Oxford Technology Investment Fund, and business angels. Later rounds included a reported £30M ($38M) raise, £35M in 2020, and $85M Series C in November 2022 led by M&G Investments with Oxford Science Enterprises and others to advance the Osler Origin platform toward regulatory approval and market launch. |
Who has invested in Osler Diagnostics?
4 investors have backed Osler Diagnostics across its funding rounds, including Oxford Science Enterprises, M&G Investments, Lansdowne Partners and Braavos Investment Advisers.
Osler Diagnostics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| Oxford | 1 | Participant | Nov 2022 | |
| London | 1 | Participant | Nov 2022 | |
This data is available for Pro users. Sign up to see all 4 Osler Diagnostics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialOsler Diagnostics Competitors
Osler Diagnostics competitors include listed companies like Applied BioCode and electroCore, and private ones like Zhideyuanjian, Craif, Pepex Biomedical and Syncell.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 United States | Publicly listed | $15M | ($5M) | $90M | - | |
 Wuxi | Private | - | - | $87M | - | |
 Tokyo | Private | - | - | $100M | - | |
| Saint Louis, MO | Private | - | - | $100M | - | |
| United States | Publicly listed | $32M | ($12M) | $103M | 2.6x | |
| San Francisco, CA | Private | - | - | $75M | - |
Osler Diagnostics Public Comps
Osler Diagnostics is still privately-owned, but its public comps include Applied BioCode, LENSAR, Curiosis, CROSSJECT, MEZOO, Nutriband, Pulmonx, Fractyl Health, Nexstim and Anixa Biosciences.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $15M | ($5M) | 5.0x | - | (14.2x) | - | |||
| $58M | ($30M) | 1.5x | 1.6x | (3.0x) | 26.7x | |||
| $5M | ($5M) | 15.2x | 8.7x | (16.3x) | (45.9x) | |||
| - | ($7M) | - | 2.0x | (15.9x) | 3.6x | |||
| $5M | - | 17.3x | 17.3x | - | - | |||
| $2M | ($8M) | 44.0x | - | (11.2x) | - | |||
| $90M | ($52M) | 0.9x | 0.9x | (1.6x) | (2.9x) | |||
| - | ($141M) | - | - | (0.8x) | (1.4x) | |||
This data is available for Pro users. Sign up to see all Osler Diagnostics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Osler Diagnostics
| When was Osler Diagnostics founded? | Osler Diagnostics was founded in 2017. |
| Where is Osler Diagnostics headquartered? | Osler Diagnostics is headquartered in Oxford, United Kingdom. |
| Is Osler Diagnostics publicly listed? | No, Osler Diagnostics is a private, VC-backed company. |
| What is Osler Diagnostics' valuation? | Osler Diagnostics was last valued at $89M in its Series A in December 2018. |
| How much funding has Osler Diagnostics raised? | Osler Diagnostics has raised $178M across 5 funding rounds. |
| What was Osler Diagnostics' last funding round? | Osler Diagnostics' last funding round was a $85M Series C in November 2022. |
| Who are Osler Diagnostics' investors? | Osler Diagnostics' investors include Oxford Science Enterprises, Lansdowne Partners, M&G Investments and Braavos Investment Advisers. |
| Which companies are comparable to Osler Diagnostics? | Companies comparable to Osler Diagnostics include Applied BioCode, Zhideyuanjian, Craif, Pepex Biomedical, electroCore and Syncell. |
See companies similar to Osler Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.